NT5E and neoplasm: This personalized approach holds great potential for optimizing treatment strategies and improving patient outcomes in breast cancer therapy [6, 7]. siRNA-CD73 is a novel therapeutic approach that utilizes siRNA to target and inhibit the expression of CD73 in converting extracellular adenosine monophosphate (AMP) to adenosine, which has immunosuppressive effects and promotes tumor growth.